| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Keith Lamont Cummings is Chief Financial Officer at PLRX. Keith Lamont Cummings's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $256K at current prices.
Our model assigns Keith Lamont Cummings a strong insider score of 75/100, based on 8 past trades. Over a 12-month horizon, all 7 of those trades were profitable, with an average 12-month return of +48.0%.
The PLRX filings lean toward selling, a net 152,950 shares.
Keith Lamont Cummings has 27 Form 4 filings on record from June 2020 to April 2026, all as Chief Financial Officer at Pliant Therapeutics (PLRX), 2020–2026.
The 54 reported transactions were 15 option or other derivative awards, 12 open-market sales, 12 option exercises and 7 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 9 sales worth about $3.0M.
The largest open-market sale was 30,000 shares of PLRX at an average $35.00 on January 23, 2023, about $1.1M. Twelve months later PLRX was down 42%.
All 5 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | PLRX Pliant Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 24,002 | $1.28 | $30,722.56 | -7.5% | +0.8% | - | |
| Jan 17, 2025 | PLRX Pliant Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 20,148 | $11.20 | $225,679.76 | -7.1% | -87.0% | -88.5% | |
| Jul 10, 2024 | PLRX Pliant Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 10,911 | $11.56 | $126,131.16 | -3.7% | +1.4% | -87.4% | |
| Jan 17, 2024 | PLRX Pliant Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 9,781 | $17.23 | $168,526.63 | -4.8% | -25.7% | -35.0% | |
| Jul 17, 2023 | PLRX Pliant Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 19,771 | $18.01 | $356,057.92 | -8.8% | -13.7% | -24.3% | |
| Mar 30, 2023 | PLRX Pliant Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 9,960 | $26.52 | $264,148.16 | -6.3% | -28.3% | -43.9% | |
| Jan 23, 2023 | PLRX Pliant Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 30,000 | $35.00 | $1,050,000.00 | -26.2% | +0.9% | -42.4% | |
| Dec 20, 2022 | PLRX Pliant Therapeutics, Inc. | Chief Financial Officer | Sell | 9,643 | $19.10 | $184,204.44 | -10.7% | +45.1% | -14.4% | |
| Dec 1, 2020 | PLRX Pliant Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 18,734 | $30.00 | $562,035.05 | -44.8% | - | - |